Evaluation of the Effect of Memantine Supplementation in the Treatment of Acute Phase of Mania in Bipolar Disorder of Elderly Patients: A Double-blind Randomized Controlled Trial

Document Type : Original Article

Authors

1 Department of Psychiatry, Isfahan University of Medical Sciences, Isfahan, Iran

2 Department of Biostatistics and Epidemiology, Faculty of Health, Lorestan University of Medical Sciences, Khorramabad, Iran

3 Department of Psychiatry, School of Medicine, Isfahan University of Medical Sciences, Noor Hospital, Isfahan, Iran

Abstract

Background: This study aimed to evaluate the efficacy of memantine in the acute treatment of geriatric with bipolar disorder (BD) hospitalized for mania. Materials and Methods: This study conducted on 70 patients older than 60 years with BD in the acute phase of mania. Oral sodium valproate was prescribed in both groups. The intervention group received memantine tablet and the placebo group received a placebo tablet based on a same procedure. Severity of mania, cognitive changes, and quality of life (QoL) were assessed and recorded 4 and 8 weeks after the beginning of the study. The collected data were analyzed with SPSS (version 20) using independent samples t-test, analysis of variance in repeated observations, Chi-squared test, and Fisher's exact test. Results: Mania severity score had no significant difference at the beginning of the study, but 4 and 8 weeks after the intervention, it was reduced significantly in both groups (P < 0.001) that was higher in memantine group (P = 0.038). The mean increase in score of cognitive variations was 6.74 in the memantine group and 3.62 in the placebo group with a nonsignificant difference (P = 0.125). The scores of each dimension of QoL in the two groups showed that in all four dimensions, the patient's physical, psychological, social, and environmental status increased significantly by time (P < 0.001). Conclusions: According to the results of this study, memantine as an adjuvant to administration of sodium valproate may have a significant effect on decreasing the intensity of mania in the long run.

Keywords

1.
Ferrari AJ, Norman RE, Freedman G, Baxter AJ, Pirkis JE, Harris MG, et al. The burden attributable to mental and substance use disorders as risk factors for suicide: Findings from the global burden of disease study 2010. PLoS One 2014;9:e91936.  Back to cited text no. 1
    
2.
Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al. Global burden of disease attributable to mental and substance use disorders: Findings from the Global Burden of Disease Study 2010. Lancet 2013;382:1575-86.  Back to cited text no. 2
    
3.
Kessler RC, Demler O, Frank RG, Olfson M, Pincus HA, Walters EE, et al. Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med 2005;352:2515-23.  Back to cited text no. 3
    
4.
Trinh NH, Forester B. Bipolar disorder in the elderly: Differential diagnosis and treatment. Psychiatr Times 2007;24:38-43.  Back to cited text no. 4
    
5.
Shiffer HH. Glutamate receptor genes: Susceptibility factors in schizophrenia and depressive patients. Mol Biol 2002;25:191-212.  Back to cited text no. 5
    
6.
Goodwin FK. Rationale for long-term treatment of bipolar disorder and evidence for long-term lithium treatment. J Clin Psychiatry 2002;63 Suppl 10:5-12.  Back to cited text no. 6
    
7.
Rapoport SI, Basselin M, Kim HW, Rao JS. Bipolar disorder and mechanisms of action of mood stabilizers. Brain Res Rev 2009;61:185-209.  Back to cited text no. 7
    
8.
Sajatovic M, Gyulai L, Calabrese JR, Thompson TR, Wilson BG, White R, et al. Maintenance treatment outcomes in older patients with bipolar I disorder. Am J Geriatr Psychiatry 2005;13:305-11.  Back to cited text no. 8
    
9.
Veronese N, Solmi M, Luchini C, Lu RB, Stubbs B, Zaninotto L, et al. Acetylcholinesterase inhibitors and memantine in bipolar disorder: A systematic review and best evidence synthesis of the efficacy and safety for multiple disease dimensions. J Affect Disord 2016;197:268-80.  Back to cited text no. 9
    
10.
Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: A 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005;162:1281-90.  Back to cited text no. 10
    
11.
Mitchell PB, Malhi GS, Ball JR. Major advances in bipolar disorder. Med J Aust 2004;181:207-10.  Back to cited text no. 11
    
12.
Bahrami Kalashgaran S, Maroufi A, Rezaei F, Ghaderi E, Hassanzadeh K. Efficacy of memantine as an adjuvant therapy in bipolar disorder; a double blind, randomized, clinical trial. Sci J Kurdistan Univ Med Sci 2016;21:1-10.  Back to cited text no. 12
    
13.
Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-41.  Back to cited text no. 13
    
14.
Réus GZ, Fries GR, Stertz L, Badawy M, Passos IC, Barichello T, et al. The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. Neuroscience 2015;300:141-54.  Back to cited text no. 14
    
15.
Rogóz Z, Skuza G, Maj J, Danysz W. Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology 2002;42:1024-30.  Back to cited text no. 15
    
16.
Gao Y, Payne RS, Schurr A, Hougland T, Lord J, Herman L, et al. Memantine reduces mania-like symptoms in animal models. Psychiatry Res 2011;188:366-71.  Back to cited text no. 16
    
17.
Agarwal V, Tripathi A. Memantine in the management of a clinically challenging case of bipolar disorder. Indian J Psychiatry 2009;51:137-8.  Back to cited text no. 17
[PUBMED]  [Full text]  
18.
Keck PE Jr., Hsu HA, Papadakis K, Russo J Jr. Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: A pilot evaluation. Clin Neuropharmacol 2009;32:199-204.  Back to cited text no. 18
    
19.
Pelton GH, Harper OL, Roose SP, Marder K, D'Antonio K, Devanand DP, et al. Combined treatment with memantine/es-citalopram for older depressed patients with cognitive impairment: A pilot study. Int J Geriatr Psychiatry 2016;31:648-55.  Back to cited text no. 19
    
20.
Koukopoulos A, Serra G, Koukopoulos AE, Reginaldi D, Serra G. The sustained mood-stabilizing effect of memantine in the management of treatment resistant bipolar disorders: Findings from a 12-month naturalistic trial. J Affect Disord 2012;136:163-6.  Back to cited text no. 20
    
21.
Serra G, Koukopoulos A, De Chiara L, Koukopoulos AE, Tondo L, Girardi P, et al. Three-year, naturalistic, mirror-image assessment of adding memantine to the treatment of 30 treatment-resistant patients with bipolar disorder. J Clin Psychiatry 2015;76:e91-7.  Back to cited text no. 21
    
22.
Serra G, Demontis F, Serra F, De Chiara L, Spoto A, Girardi P, et al. Memantine: New prospective in bipolar disorder treatment. World J Psychiatry 2014;4:80-90.  Back to cited text no. 22
    
23.
Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: Reliability, validity and sensitivity. Br J Psychiatry 1978;133:429-35.  Back to cited text no. 23
    
24.
Barakatain M, Tavakkoli M, Molavi H, Maroofi M, Salehi M. Standardization, validity and reliability of young mania rating scale in Iran. J Psychol 2007;2:150-66.  Back to cited text no. 24
    
25.
Barekatain M, Behdad M, Tavakkoli M, Mahvari J, Maracy MR, Walterfang M, et al. Psychometric Properties of the Persian Version of the Neuropsychiatry Unit Cognitive Assessment Tool (NUCOG) in Patients with Dementia. Iranian Journal of Psychiatry and Clinical Psychology. 2010;16(1):14-20.  Back to cited text no. 25
    
26.
Walterfang M, Velakoulis D, Gibbs A, Lloyd J. The NUCOG: Construction and piloting of a cognitive screening instrument in a neuropsychiatric unit. Australas Psychiatry 2003;11:325-9.  Back to cited text no. 26
    
27.
World Health Organization. WHOQOL-BREF: Introduction, Administration, Scoring and Generic Version of the Assessment: Field Trial Version. Geneva: World Health Organization; 1996.  Back to cited text no. 27
    
28.
Jahanlou AS, Karami NA. WHO quality of life-BREF 26 questionnaire: Reliability and validity of the Persian version and compare it with Iranian diabetics quality of life questionnaire in diabetic patients. Prim Care Diabetes 2011;5:103-7.  Back to cited text no. 28
    
29.
Demontis F, Falconi M, Canu D, Serra G. Memantine prevents “bipolar-like” behavior induced by chronic treatment with imipramine in rats. Eur J Pharmacol 2015;752:49-54.  Back to cited text no. 29
    
30.
Zdanys K, Tampi RR. A systematic review of off-label uses of memantine for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1362-74.  Back to cited text no. 30
    
31.
Sani G, Serra G, Kotzalidis GD, Romano S, Tamorri SM, Manfredi G, et al. The role of memantine in the treatment of psychiatric disorders other than the dementias: A review of current preclinical and clinical evidence. CNS Drugs 2012;26:663-90.  Back to cited text no. 31
    
32.
Serra G, De Chiara L, Koukopoulos A, Serra G. Antimanic and long-lasting mood stabilizing effect of memantine in bipolar I mood disorder: Two case reports. J Clin Psychopharmacol 2013;33:715-7.  Back to cited text no. 32
    
33.
Serra G, De Chiara L, Manfredi G, Koukopoulos AE, Sani G, Girardi P, et al. Memantine in the management of affective recurrences of bipolar disorders after the discontinuation of long-term lithium treatment: Three case histories. Ther Adv Psychopharmacol 2014;4:53-5.  Back to cited text no. 33
    
34.
De Chiara L, Serra G, Koukopoulos AE, Koukopoulos A, Serra G. Memantine in the treatment and prophylaxis of bipolar type II mood disorder and co-morbid eating disorder: A case report. Riv Psichiatr 2014;49:192-4.  Back to cited text no. 34
    
35.
Anand A, Gunn AD, Barkay G, Karne HS, Nurnberger JI, Mathew SJ, et al. Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: A double-blind, randomized, placebo-controlled trial. Bipolar Disord 2012;14:64-70.  Back to cited text no. 35
    
36.
Lee SY, Chen SL, Chang YH, Chen PS, Huang SY, Tzeng NS, et al. Add-on memantine to valproate treatment increased HDL-C in bipolar II disorder. J Psychiatr Res 2013;47:1343-8.  Back to cited text no. 36
    
37.
Depp CA, Davis CE, Mittal D, Patterson TL, Jeste DV. Health-related quality of life and functioning of middle-aged and elderly adults with bipolar disorder. J Clin Psychiatry 2006;67:215-21.  Back to cited text no. 37
    
38.
Dean BB, Gerner D, Gerner RH. A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in bipolar disorder. Curr Med Res Opin 2004;20:139-54.  Back to cited text no. 38
    
39.
Keck PE Jr., McElroy SL, Arnold LM. Bipolar disorder. Med Clin North Am 2001;85:645-61, ix.  Back to cited text no. 39